document.writeln("
Occam plans to launch new drug-eluting stent
Mumbai:
The
Netherlands-based Occam International, a holding company
of the US pharmaceutical major, Sun Biomedical Ltd, is
in the process of commercially launching its drug-eluting
stent, `Axxion', for the first time in India. The company
will be marketing the stent through its Indian distributor,
the Mumbai-based Shruti Medi Sciences. Occam, which has
a turnover of $25 million, will be launching this product
in China and Europe in September this year, according
to a senior official of the company.
Axxion
is different from other drug-eluting stents in India in
that it has two coatings. The first coating on the metal
is made up of Calix, which is the molecule that is present
in the outside layer of every cell in the human body.
The second coating is made of the drug Paclitaxel, which
inhibits smooth muscle proliferation and migration to
prevent restenosis. According to the company, the stent
will be of major help to those suffering from coronary
artery diseases, as it would prevent possible complications
after the drug, Paclitaxel, has eluted.
Back
to News Review index page
PGCIL to float tenders for a billion
dollar upgrade
Bangalore:
The Power Grid Corporation of India Ltd (PGCIL) has said
it would shortly float tenders for modernisation of the
power system in Western Region, involving an investment
of $1 billion.
PGCIL
has said that tenders for this ambitious project would
be opened in a month or 45 days, inviting partners, including
global players. The Power Grid would maintain a 50 per
cent share.
To
accelerate the pace of implementation of the National
Grid, with enhanced inter-regional power capacity, it
was proposed to establish an inner-regional power transfer
capacity of 30,000 mw by the year 2009-10, ahead of the
scheduled 2011-12 and 50,000 mw by 2014-15.
Back
to News Review index page
